肾细胞癌辅助免疫治疗后的一线全身治疗:一项国际多中心研究
这项回顾性国际多中心研究纳入94例辅助免疫治疗后复发的肾细胞癌患者,评估一线全身治疗的结局。中位随访15个月,18个月无进展生存率和总生存率分别为45%和85%。 favorable-risk患者接受VEGF-TT可能比IO治疗获益更多。
要点
- 辅助免疫治疗后复发的RCC患者对后续全身治疗有应答。
- 18个月PFS率和OS率分别为45%和85%。
- favorable-risk患者接受VEGF-TT可能比IO治疗获益更多。
核心结论
- 辅助免疫治疗后复发的RCC患者中,部分对全身治疗有应答,包括VEGF-TT和IO为基础的方案。
- 值得注意的是,在此背景下,favorable-risk患者接受VEGF-TT可能比接受IO治疗获益更多。
- 未来需要利用影像学工具和基于生物标志物的液体活检来检测隐匿性转移性疾病,并识别适合辅助IO治疗的候选患者。
研究设计与样本
- 回顾性研究,纳入29家国际机构中辅助IO治疗后复发的RCC患者,共94例。
- 主要终点为一线全身治疗的无进展生存期(PFS),采用Kaplan-Meier法估计。
- 预先计划的亚组分析按一线全身治疗类型、复发时间和IMDC风险组进行。
主要发现
- 94例患者中,大多数接受辅助帕博利珠单抗(n=37,39%)、阿替利珠单抗(n=28,30%)或纳武利尤单抗+伊匹木单抗(n=15,16%)。
- 49例(52%)在末次辅助IO剂量后3个月内复发,45例(48%)在3个月后复发。
- 3个月内复发者骨转移显著高于3个月后复发者(10/49,20% vs 1/45,2.2%;p=0.008)。
- 一线全身治疗最常见为VEGF-TT(n=37,39%)、IO+VEGF-TT(n=26,28%)或IO+IO(n=12,13%),其余接受局部治疗。
- 一线全身治疗队列中位随访15个月,18个月PFS率和OS率分别为45%(95%CI:34-60)和85%(95%CI:75-95)。
关键数值与推荐
- 3个月内复发者骨转移为10/49(20%),3个月后复发者为1/45(2.2%),p=0.008。
- 18个月PFS率为45%(95%CI:34-60),18个月OS率为85%(95%CI:75-95)。
- 治疗相关不良事件发生于32例(42%)患者。
临床怎么用
- 辅助IO治疗后复发的RCC患者可接受后续全身治疗,包括VEGF-TT和IO为基础的方案。
- 作者认为,在此背景下,favorable-risk患者接受VEGF-TT可能比接受IO治疗获益更多。
- 作者提出,未来需要利用影像学工具和基于生物标志物的液体活检来检测隐匿性转移性疾病,并识别适合辅助IO治疗的候选患者。
局限性
- 局限性包括从大型学术中心选择患者以及随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Adjuvant pembrolizumab significantly improved overall survival (OS) in renal cell carcinoma (RCC), but real-world data on sequential treatment are scarce. We sought to evaluate the clinical outcomes of first-line (1L) systemic therapy following adjuvant immune oncology (IO)-based regimens. METHODS: A retrospective study including patients with recurrent RCC following adjuvant IO across 29 international institutions was conducted. The primary endpoint was progression-free survival (PFS) on 1L systemic therapy estimated using the Kaplan-Meier method. Preplanned subanalyses of clinical outcomes by type of 1L systemic therapy, recurrence timing, and International Metastatic RCC Database Consortium (IMDC) risk groups were performed. Treatment-related adverse events leading to treatment discontinuation, dose reduction, or corticosteroid use were assessed. KEY FINDINGS AND LIMITATIONS: A total of 94 patients were included. Most received adjuvant pembrolizumab (n = 37, 39%), atezolizumab (n = 28, 30%), or nivolumab + ipilimumab (n = 15, 16%). The cohort included 49 (52%) patients who had recurrence within 3 mo of the last adjuvant IO dose, whereas 45 (48%) recurred beyond 3 mo. Bone metastases were significantly higher in tumors recurring at <3 mo (10/49, 20%) than those recurring at >3 mo (1/45, 2.2%; p = 0.008). Most patients received 1L vascular endothelial growth factor-targeted therapy (VEGF-TT; n = 37, 39%), IO + VEGF-TT (n = 26, 28%), or IO + IO (n = 12, 13%). The remaining underwent local therapy. The median follow-up for the 1L systemic therapy cohort was 15 mo. The 18-mo PFS and OS rates were 45% (95% confidence interval [CI]: 34-60) and 85% (95% CI: 75-95), respectively. Treatment-related adverse events occurred in 32 (42%) patients and included skin toxicity (n = 7, 9.2%), fatigue (n = 6, 7.9%), and diarrhea/colitis (n = 4, 5.3%). Limitations included selecting patients from large academic centers and the short follow-up period. CONCLUSIONS AND CLINICAL IMPLICATIONS: A subset of patients with recurrent RCC following adjuvant IO respond to systemic therapies, including VEGF-TT and IO-based regimens. Notably, patients with favorable-risk disease may derive more benefit from VEGF-TT than from IO therapies in this setting. Future approaches utilizing radiographic tools and biomarker-based liquid biopsies are warranted to detect occult metastatic disease and identify candidate patients for adjuvant IO therapy. PATIENT SUMMARY: Adjuvant pembrolizumab significantly improved overall survival in renal cell carcinoma (RCC). There are limited data on clinical outcomes after the recurrence of RCC tumors following adjuvant immunotherapy. In this study, we find that patients respond to subsequent systemic therapies across different treatment options.
引用
- El Zarif T, Semaan K, Xie W, et al. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. Eur Urol. 2024. PMID: 39147674. doi:10.1016/j.eururo.2024.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。